IMMNOV — Immunovia AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK136.55m
- SEK80.94m
- SEK0.69m
Brief: Immunovia To Significantly Restructure To Focus Resources On Its Next-Generation Blood Test For Pancreatic Cancer Detection
Brief: Jeff Borcherding, CEO Of Immunovia, Purchases 350 000 Shares
Brief: Immunovia Sees Modest Revenue Growth For 2023
Brief: Immunovia Q1 Adj. EPS at SEK -2.28
Brief: Immunovia AB Appoints Jeff Borcherding As New CEO
Brief: Immunovia Announces Outcome Of Rights Issue
Brief: Immunovia Q4 Net Sales Amounted To SEK 502,000
Brief: Immunovia Q4 Net Loss SEK 67 Million
Brief: Immunovia Resolves On Rights Issue Of About SEK 202.2 Million
Brief: Immunovia Initiates Consultation Process With Relevant Swedish Unions To Create Best Possible Transition For Affected Employees
Brief: CMS Sets Rate Of $897 For Immunovia's Immray Pancan-D Test
Brief: Immunovia CEO Buys Company Warrants
Brief: Immunovia Q3 Net Loss Narrows To SEK 23 Mln
Brief: Immunovia Launches Strategic Partnership With Proteomedix
Brief: Centers For Medicare & Medicaid Services Issues Preliminary Payment Rate Determination For Immunovia's Immray Pancan-D Test
Brief: Immunovia April-June Net Loss Narrows To SEK 33 Million
Brief: Immunovia Unit Issued License In California
Brief: Immunovia Appoints CEO
Brief: Immunovia U.S. Unit Achieves Clinical Laboratory Licensure From Rhode Island Department Of Health